The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
TP53 -mutant myelodysplastic syndrome and acute myeloid leukemia: the black hole of hematology
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among the many recurrent genetic abnormalities in AML, TP53 mutations are associated with the most unfavorable prognosis.”
From The TP53 tumor suppressor gene: From molecular biology to clinical investigations (2025) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
Sallman, D. A., McLemore, A. F., Aldrich, A. L., Komrokji, R. S., McGraw, K. L., Dhawan, A., Geyer, S., Hou, H.-A., Eksioglu, E. A., Sullivan, A., et al. (2020) · Blood · doi:10.1182/blood.2020006158 · Cited by 196 · cited 1×
“HMAs may cause less injury to the mucosal barrier, and because patients with TP53 mutations may harbor inherent immune defects, HMAs may pose less risk for infection.(6)”
BackgroundHunter, A. M., Komrokji, R. S., Yun, S., Al Ali, N., Chan, O., Song, J., Hussaini, M., Talati, C., Sweet, K. L., Lancet, J. E., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003508 · Cited by 76
Research works printed but not linked: 4
- Short, 2020, Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia, Blood Adv., 4, 5681, 10.1182/bloodadvances.2020003120 · DOI · Paper page
- Patel, 2021, Clinico-genomic profiling and clonal dynamic modeling of TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia, Leuk Lymphoma., 62, 3348, 10.1080/10428194.2021.1957869 · DOI
- Bewersdorf, 2020, Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience, Leuk Lymphoma., 61, 2180, 10.1080/10428194.2020.1759051 · DOI
- Welch, 2016, TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes, N Engl J Med., 375, 2023, 10.1056/NEJMoa1605949 · DOI · Paper page
Cited by
The TP53 tumor suppressor gene: From molecular biology to clinical investigations
Baliakas, P., & Soussi, T. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20106 · Cited by 50
Metadata
- Authors
- Patel, S. A., & Cerny, J.
- Affiliations
- University of Massachusetts Chan Medical School, UMass Memorial Medical Center, Worcester, MA
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2022-03-21
- Volume
- 6
- Issue
- 6
- Pages
- 1917-1918
- ISSN
- 2473-9529
- 2473-9537
- Cited by
- 11
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TP53 -mutant myelodysplastic syndrome and acute myeloid leukemia: the black hole of hematology. https://app.cochat.ai/papers/10.1182/bloodadvances.2021006580
- The paper
- Patel, S. A., & Cerny, J. (2022). TP53 -mutant myelodysplastic syndrome and acute myeloid leukemia: the black hole of hematology. Blood Advances. https://doi.org/10.1182/bloodadvances.2021006580
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
